FLUID-BAG MULTI
Fluid-Bag provides comprehensive 900 and 1000 litre flexible IBC systems for liquid and semi-solid products. The GMP compliant MULTI containers guarantee uniform liquid, maximise payload and minimise product residue.
FLUID-BAG MULTI superior logistics for liquid and semi-solid pharmaceutical products
Fluid-Bag Ltd provides comprehensive 900 and 1000 litre flexible IBC systems for liquid and semi-solid products, including filling and discharging equipment. The GMP compliant container system is designed to guarantee uniform liquid, maximise payload and minimise discharge residue (0.5% residue).
The MULTI container combines the flexibility and space-saving advantages of both single-trip and multi-trip containers. The container consists of:
- a replaceable, single-trip inner container
- a reusable multi-trip transport bag
- a reusable steel transport pallet with 4 steel poles.
Alternative liner combinations are available, gamma irradiation is also possible. The container can be used for external transports, intermediate storage, for transport between production, store room and packing department etc.
The FLUID-BAG system is used for storage and transportation of a wide range of liquids where protection from bacteria, particle, oxidation, taste or moisture contamination is needed. The containers are widely used for ointments, lotions, suspensions and other liquid or semi-solid products.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
